Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cells

References

• Jemal A, Siegel R, Xu J, Ward E, Thun MJ. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Service RF. New role for estrogen in cancer?. Science 1998; 279:1631 - 3; http://dx.doi.org/10.1126/science.279.5357.1631; PMID: 9518374
   PubMed Web of Science ®Google Scholar
• Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol 2001; 11:339 - 52; http://dx.doi.org/10.1006/scbi.2001.0389; PMID: 11562176
   PubMed Web of Science ®Google Scholar
• Jordan VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 2009; 69:1243 - 54; http://dx.doi.org/10.1158/0008-5472.CAN-09-0029; PMID: 19208829
   PubMed Web of Science ®Google Scholar
• Peng J, Sengupta S, Jordan VC. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med Chem 2009; 9:481 - 99; PMID: 19519291
   PubMed Web of Science ®Google Scholar
• Goswami SK, Das DK. Resveratrol and chemoprevention. Cancer Lett 2009; 284:1 - 6; http://dx.doi.org/10.1016/j.canlet.2009.01.041; PMID: 19261378
   PubMed Web of Science ®Google Scholar
• Leifert WR, Abeywardena MY. Cardioprotective actions of grape polyphenols. Nutr Res 2008; 28:729 - 37; http://dx.doi.org/10.1016/j.nutres.2008.08.007; PMID: 19083481
   PubMed Web of Science ®Google Scholar
• Gautam R, Jachak SM. Recent developments in anti-inflammatory natural products. Med Res Rev 2009; 29:767 - 820; http://dx.doi.org/10.1002/med.20156; PMID: 19378317
   PubMed Web of Science ®Google Scholar
• Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275:218 - 20; http://dx.doi.org/10.1126/science.275.5297.218; PMID: 8985016
   PubMed Web of Science ®Google Scholar
• Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 2008; 269:243 - 61; http://dx.doi.org/10.1016/j.canlet.2008.03.057; PMID: 18550275
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5:493 - 506; http://dx.doi.org/10.1038/nrd2060; PMID: 16732220
   PubMed Web of Science ®Google Scholar
• Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007; 224:274 - 83; http://dx.doi.org/10.1016/j.taap.2006.12.025; PMID: 17306316
   PubMed Web of Science ®Google Scholar
• Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16:1246 - 52; http://dx.doi.org/10.1158/1055-9965.EPI-07-0022; PMID: 17548692
   PubMed Web of Science ®Google Scholar
• Niles RM, Cook CP, Meadows GG, Fu YM, McLaughlin JL, Rankin GO. Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr 2006; 136:2542 - 6; PMID: 16988123
   PubMed Web of Science ®Google Scholar
• Walle T, Hsieh F, DeLegge MH, Oatis JE Jr., Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32:1377 - 82; http://dx.doi.org/10.1124/dmd.104.000885; PMID: 15333514
   PubMed Web of Science ®Google Scholar
• Wenzel E, Soldo T, Erbersdobler H, Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 2005; 49:482 - 94; http://dx.doi.org/10.1002/mnfr.200500003; PMID: 15779067
   PubMed Web of Science ®Google Scholar
• Pan MH, Lin CL, Tsai JH, Ho CT, Chen WJ. 3,5,3′,4′,5′-pentamethoxystilbene (MR-5), a synthetically methoxylated analogue of resveratrol, inhibits growth and induces G1 cell cycle arrest of human breast carcinoma MCF-7 cells. J Agric Food Chem 2010; 58:226 - 34; http://dx.doi.org/10.1021/jf903067g; PMID: 19916542
   PubMed Web of Science ®Google Scholar
• Ma Z, Molavi O, Haddadi A, Lai R, Gossage RA, Lavasanifar A. Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother Pharmacol 2008; 63:27 - 35; http://dx.doi.org/10.1007/s00280-008-0704-z; PMID: 18286288
   PubMed Web of Science ®Google Scholar
• Heynekamp JJ, Weber WM, Hunsaker LA, Gonzales AM, Orlando RA, Deck LM, et al. Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor kappaB. J Med Chem 2006; 49:7182 - 9; http://dx.doi.org/10.1021/jm060630x; PMID: 17125270
   PubMed Web of Science ®Google Scholar
• Minutolo F, Sala G, Bagnacani A, Bertini S, Carboni I, Placanica G, et al. Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells. J Med Chem 2005; 48:6783 - 6; http://dx.doi.org/10.1021/jm050528k; PMID: 16250636
   PubMed Web of Science ®Google Scholar
• Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996; 12:2315 - 24; PMID: 8649771
   PubMed Web of Science ®Google Scholar
• Prall OW, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997; 272:10882 - 94; http://dx.doi.org/10.1074/jbc.272.16.10882; PMID: 9099745
   PubMed Web of Science ®Google Scholar
• Sakamoto T, Horiguchi H, Oguma E, Kayama F. Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells. J Nutr Biochem 2010; 21:856 - 64; http://dx.doi.org/10.1016/j.jnutbio.2009.06.010; PMID: 19800779
   PubMed Web of Science ®Google Scholar
• Lappano R, Rosano C, Madeo A, Albanito L, Plastina P, Gabriele B, et al. Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol Nutr Food Res 2009; 53:845 - 58; http://dx.doi.org/10.1002/mnfr.200800331; PMID: 19496085
   PubMed Web of Science ®Google Scholar
• Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 1997; 94:14138 - 43; http://dx.doi.org/10.1073/pnas.94.25.14138; PMID: 9391166
   PubMed Web of Science ®Google Scholar
• Levenson AS, Gehm BD, Pearce ST, Horiguchi J, Simons LA, Ward JEIII 3rd, et al. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int J Cancer 2003; 104:587 - 96; http://dx.doi.org/10.1002/ijc.10992; PMID: 12594813
   PubMed Web of Science ®Google Scholar
• Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 1999; 179:297 - 304; http://dx.doi.org/10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P; PMID: 10228948
   PubMed Web of Science ®Google Scholar
• Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 2001; 61:7456 - 63; PMID: 11606380
   PubMed Web of Science ®Google Scholar
• Basly JP, Marre-Fournier F, Le Bail JC, Habrioux G. Chulia, A. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. J Life Sci 2000; 66:769 - 77; http://dx.doi.org/10.1016/S0024-3205(99)00650-5
   PubMed Web of Science ®Google Scholar
• Tennen RI, Michishita-Kioi E, Chua KF. Finding a target for resveratrol. Cell 2012; 148:387 - 9; http://dx.doi.org/10.1016/j.cell.2012.01.032; PMID: 22304906
   PubMed Web of Science ®Google Scholar
• Chung EY, Kim BH, Hong JT, Lee CK, Ahn B, Nam SY, et al. Resveratrol down-regulates interferon-γ-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J Nutr Biochem 2011; 22:902 - 9; http://dx.doi.org/10.1016/j.jnutbio.2010.07.012; PMID: 21189227
   PubMed Web of Science ®Google Scholar
• Vakana E, Platanias LC. AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget 2011; 2:1322 - 8; PMID: 22249159
   PubMed Web of Science ®Google Scholar
• Kong Y, Grembecka J, Edler MC, Hamel E, Mooberry SL, Sabat M, et al. Structure-based discovery of a boronic acid bioisostere of combretastatin A-4. Chem Biol 2005; 12:1007 - 14; http://dx.doi.org/10.1016/j.chembiol.2005.06.016; PMID: 16183025
   PubMed Web of Science ®Google Scholar
• Kong Y, Wang K, Edler MC, Hamel E, Mooberry SL, Paige MA, et al. A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg Med Chem 2010; 18:971 - 7; http://dx.doi.org/10.1016/j.bmc.2009.11.003; PMID: 20006519
   PubMed Web of Science ®Google Scholar
• Dorsey BD, Iqbal M, Chatterjee S, Menta E, Bernardini R, Bernareggi A, et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008; 51:1068 - 72; http://dx.doi.org/10.1021/jm7010589; PMID: 18247547
   PubMed Web of Science ®Google Scholar
• Suzuki N, Suzuki T, Ota Y, Nakano T, Kurihara M, Okuda H, et al. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors. J Med Chem 2009; 52:2909 - 22; http://dx.doi.org/10.1021/jm900125m; PMID: 19419205
   PubMed Web of Science ®Google Scholar
• Ness S, Martin R, Kindler AM, Paetzel M, Gold M, Jensen SE, et al. Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 beta-Lactamase(,). Biochemistry 2000; 39:5312 - 21; http://dx.doi.org/10.1021/bi992505b; PMID: 10820001
   PubMed Web of Science ®Google Scholar
• Venkatraman S, Wu W, Prongay A, Girijavallabhan V, George Njoroge F. Potent inhibitors of HCV-NS3 protease derived from boronic acids. Bioorg Med Chem Lett 2009; 19:180 - 3; http://dx.doi.org/10.1016/j.bmcl.2008.10.124; PMID: 19022670
   PubMed Web of Science ®Google Scholar
• Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 2002; 8:893 - 903; PMID: 11895924
   PubMed Web of Science ®Google Scholar
• Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000; 12:450 - 8; http://dx.doi.org/10.1097/00001622-200009000-00011; PMID: 10975553
   PubMed Web of Science ®Google Scholar
• Ferry DR. Testing the role of P-glycoprotein expression in clinical trials: applying pharmacological principles and best methods for detection together with good clinical trials methodology. Int J Clin Pharmacol Ther 1998; 36:29 - 40; PMID: 9476146
   PubMed Web of Science ®Google Scholar
• Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM, et al. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. J Natl Cancer Inst 1992; 84:1506 - 12; http://dx.doi.org/10.1093/jnci/84.19.1506; PMID: 1359153
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy JA, Cowan KH. Current status of paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat 1995; 33:27 - 37; http://dx.doi.org/10.1007/BF00666068; PMID: 7749130
   PubMed Web of Science ®Google Scholar
• Reddy GP. Cell cycle: regulatory events in G1-->S transition of mammalian cells. J Cell Biochem 1994; 54:379 - 86; http://dx.doi.org/10.1002/jcb.240540404; PMID: 8014186
   PubMed Web of Science ®Google Scholar
• Deb TB, Coticchia CM, Dickson RB. Calmodulin-mediated activation of Akt regulates survival of c-Myc-overexpressing mouse mammary carcinoma cells. J Biol Chem 2004; 279:38903 - 11; http://dx.doi.org/10.1074/jbc.M405314200; PMID: 15247222
   PubMed Web of Science ®Google Scholar